{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:28:45Z","timestamp":1792452525916,"version":"4.5.0"},"reference-count":30,"publisher":"Institute of Physiology of the Czech Academy of Sciences","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Physiol Res"],"abstract":"<jats:p>Myocardial infarction (MI) remains a major cause of morbidity and mortality. The ischemic myocardium undergoes necrosis and apoptosis, triggering inflammation and oxidative stress that drive fibrosis and heart failure. High-mobility group box 1 (HMGB1) protein acts as a key damage-associated molecular pattern, activating TLR4 and NF\u03baB signaling to promote cytokine release and exacerbate injury. The present study investigated the role of HMGB1 in MI and its impact on inflammatory and redox-related pathways, focusing on the effects of HMGB1 blockade. Male WKY rats were divided into the following groups: sham, MI, and MI with anti-HMGB1 treatment (MI+aHMGB1). MI was induced in rats by coronary ligation followed by reperfusion, and the animals were evaluated seven days later. Plasma cytokines, total NOS activity and gene expression in the left ventricle were analyzed. MI significantly increased plasma TNF\u03b1 and IL-6, while anti-HMGB1 treatment reduced both cytokines. Hmgb1 mRNA was markedly upregulated after MI and normalized by aHMGB1. MI suppressed Nos3 gene expression and total NOS activity, both of which were restored by aHMGB1. Tlr4 and NF\u03baB mRNA levels were elevated after MI and remained high after HMGB1 inhibition, whereas Nos2 and IL-1\u03b2 gene expression declined. Antioxidant responses showed differential regulation: Sod1 and Sod2 were further upregulated by aHMGB1, Gpx4 expression normalized, and lipid peroxidation was found to be partially attenuated. These findings indicate that HMGB1 is a key driver of post-infarction inflammation and oxidative injury. Its inhibition modulates cytokine production, restores redox balance, and enhances endothelial protection, suggesting a promising therapeutic target for limiting myocardial damage.<\/jats:p>","DOI":"10.33549\/physiolres.935718","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T20:01:37Z","timestamp":1768248097000},"page":"S259","source":"Crossref","is-referenced-by-count":2,"title":["Modulation of Cardiac Gene Expression by anti-HMGB1 in a Model of Experimental Myocardial Infarction"],"prefix":"10.33549","author":[{"given":"M","family":"Cebova","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05ra1x588","id-type":"ROR","asserted-by":"publisher"}],"name":"Institute of Normal and Pathological Physiology of the Slovak Academy of Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Barta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Bujnova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Vojtkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Vrankova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Klimentova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Pechanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"19169","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"key":"ref0","unstructured":"1.\tWHO Cardiovascular diseases, 2022, Accessed 2 October 2025. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases- %28cvds %29?utm_source"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"2.\tChikhirzhina E, Starkova T, Beljajev A, Polyanichko A, Tomilin A. Functional diversity of non-histone chromosomal protein HmgB1. Int J Mol Sci. 2020;21:7948. https:\/\/doi.org\/10.3390\/ijms21217948","DOI":"10.3390\/ijms21217948"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3.\tGao B, Wang S, Li J, Han N, Ge H, Zhang G, Chang M. HMGB1, angel or devil, in ischemic stroke. Brain Behav. 2023;13: e2987. https:\/\/doi.org\/10.1002\/brb3.2987","DOI":"10.1002\/brb3.2987"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"4.\tFoglio E, Pellegrini L, Russo MA, Limana F. HMGB1-Mediated Activation of the Inflammatory-Reparative Response Following Myocardial Infarction. Cells. 2022;11:216. https:\/\/doi.org\/10.3390\/cells11020216","DOI":"10.3390\/cells11020216"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"5.\tWahid A, Wen J, Yang Q, Zhang Z, Zhao X, Tang X. Serum HMGB1 is a biomarker for acute myocardial infarction with or without heart failure. Clin Transl Sci. 2023;16:2299-2309. https:\/\/doi.org\/10.1111\/cts.13630","DOI":"10.1111\/cts.13630"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"6.\tDate S, Bhatt LK. Targeting high-mobility-group-box-1-mediated inflammation: a promising therapeutic approach for myocardial infarction. Inflammopharmacology. 2025;33:767-784. https:\/\/doi.org\/10.1007\/s10787-024-01586-w","DOI":"10.1007\/s10787-024-01586-w"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"7.\tHofma SH, Smits PC, Brouwer J, Velders MA, van't Hof AW, Quer\u00e9 M, de Vries CJ, van Boven AJ. Long-term follow-up of second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction: Three-year results of the XAMI trial. EuroIntervention. 2015;10:1280-1283. https:\/\/doi.org\/10.4244\/EIJY15M01_03","DOI":"10.4244\/EIJY15M01_03"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"8.\tPodesser BK, Hallstr\u00f6m S. Nitric oxide homeostasis as a target for drug additives to cardioplegia. Br J Pharmacol. 2007;151:930-940. https:\/\/doi.org\/10.1038\/sj.bjp.0707272","DOI":"10.1038\/sj.bjp.0707272"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"9.\tAbdelrahaman D, Habotta OA, Taher ES, El-Ashry ES, Ibrahim I, Abdeen A, Ibrahim AM, Ibrahim RM, Anwer H, Mihaela O, Olga R, Alwutayed KM, Al-Serwi RH, El-Sherbiny M, Sorour SM, El-Kashef DH. Suppression of NLRP3 inflammasome orchestrates the protective efficacy of tiron against isoprenaline-induced myocardial injury. Front Pharmacol. 2024;15:1379908. https:\/\/doi.org\/10.3389\/fphar.2024.1379908","DOI":"10.3389\/fphar.2024.1379908"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"10.\tSun N, Wang H, Wang L. Protective effects of ghrelin against oxidative stress, inducible nitric oxide synthase and inflammation in a mouse model of myocardial ischemia\/reperfusion injury via the HMGB1 and TLR4\/NF-\u03baB pathway. Mol Med Rep. 2016;14:2764-2770. https:\/\/doi.org\/10.3892\/mmr.2016.5535","DOI":"10.3892\/mmr.2016.5535"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"11.\tCortese-Krott MM, Suvorava T, Leo F, Heuser SK, LoBue A, Li J, Becher S, Schneckmann R, Srivrastava T, Erkens R, Wolff G, Schmitt JP, Grandoch M, Lundberg JO, Pernow J, Isakson BE, Weitzberg E, Kelm M. Red blood cell eNOS is cardioprotective in acute myocardial infarction. Redox Biol. 2022;54:102370. https:\/\/doi.org\/10.1016\/j.redox.2022.102370","DOI":"10.1016\/j.redox.2022.102370"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"12.\tMusicante M, Kim HH, Chen Y, Liao F, Bhattacharya SK, Lu L, Sun Y. Regulation of endothelial nitric oxide synthase in cardiac remodeling. Int J Cardiol. 2022;364:96-101. https:\/\/doi.org\/10.1016\/j.ijcard.2022.05.013","DOI":"10.1016\/j.ijcard.2022.05.013"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"13.\tJin B, Zhang Z, Zhang Y, Yang M, Wang C, Xu J, Zhu Y, Mi Y, Jiang J, Sun Z. Ferroptosis and myocardial ischemia-reperfusion: mechanistic insights and new therapeutic perspectives. Front Pharmacol. 2024;15:1482986. https:\/\/doi.org\/10.3389\/fphar.2024.1482986","DOI":"10.3389\/fphar.2024.1482986"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14.\tGao Q, Li C, Zhong P, Yu Y, Luo Z, Chen H. GDF15 restrains myocardial ischemia-reperfusion injury through inhibiting GPX4 mediated ferroptosis. Aging (Albany NY). 2024;16:617-626. https:\/\/doi.org\/10.18632\/aging.205402","DOI":"10.18632\/aging.205402"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"15.\tXu Y, Zhou W, Fan Z, Cheng Y, Xiao Y, Liu Y, Li X, Ji Z, Fan Y, Ma G. Xanthosine alleviates myocardial ischemia-reperfusion injury through attenuation of cardiomyocyte ferroptosis. Cell Mol Biol Lett. 2025;30:93. https:\/\/doi.org\/10.1186\/s11658-025-00766-y, https:\/\/doi.org\/10.1186\/s11658-022-00388-8","DOI":"10.1186\/s11658-025-00766-y"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"16.\tDawi J, Affa S, Gonzalez E, Misakyan Y, Nikoghosyan D, Hajjar K, Kades S, Fardeheb S, Mirzoyan H, Venketaraman V. Ferroptosis in cardiovascular disease and cardiomyopathies: therapeutic implications of glutathione and iron chelating agents. Biomedicines. 2024;12:558. https:\/\/doi.org\/10.3390\/biomedicines12030558","DOI":"10.3390\/biomedicines12030558"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"17.\tKosutova M, Pechanova O, Barta A, Franova S, Cebova M. Different adaptive NO-dependent mechanisms in normal and hypertensive conditions. Molecules. 2019;24:1682. https:\/\/doi.org\/10.3390\/molecules24091682","DOI":"10.3390\/molecules24091682"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"18.\tCebova M, Klimentova J, Janega P, Pechanova O. Effect of bioactive compound of aronia melanocarpa on cardiovascular system in experimental hypertension. Oxid Med Cell Longev. 2017;2017:8156594. https:\/\/doi.org\/10.1155\/2017\/8156594","DOI":"10.1155\/2017\/8156594"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"19.\tBacmeister L, Schwarzl M, Warnke S, Stoffers B, Blankenberg S, Westermann D, Lindner D. Inflammation and fibrosis in murine models of heart failure. Basic Res Cardiol. 2019;114:19. https:\/\/doi.org\/10.1007\/s00395-019-0722-5","DOI":"10.1007\/s00395-019-0722-5"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"20.\tPinar AA, Scott TE, Huuskes BM, Tapia C\u00e1ceres FE, Kemp-Harper BK, Samuel CS. Targeting the NLRP3 inflammasome to treat cardiovascular fibrosis. Pharmacol Ther. 2020;209:107511. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107511","DOI":"10.1016\/j.pharmthera.2020.107511"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"21.\tFrangogiannis NG. Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities. Mol Aspects Med. 2019;65:70-99. https:\/\/doi.org\/10.1016\/j.mam.2018.07.001","DOI":"10.1016\/j.mam.2018.07.001"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"22.\tTao W, Yang X, Zhang Q, Bi S, Yao Z. Optimal treatment for post-MI heart failure in rats: dapagliflozin first, adding sacubitril-valsartan 2 weeks later. Front Cardiovasc Med. 2023;10:1181473. https:\/\/doi.org\/10.3389\/fcvm.2023.1181473","DOI":"10.3389\/fcvm.2023.1181473"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"23.\tAires R, Pimentel EB, Forechi L, Dantas EM, Mill JG. Time course of changes in heart rate and blood pressure variability in rats with myocardial infarction. Braz J Med Biol Res. 2017;50: e5511. https:\/\/doi.org\/10.1590\/1414-431x20165511","DOI":"10.1590\/1414-431x20165511"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"24.\tFrangogiannis NG. Transforming growth factor-\u03b2 in myocardial disease. Nat Rev Cardiol. 2022;19:435-455. https:\/\/doi.org\/10.1038\/s41569-021-00646-w","DOI":"10.1038\/s41569-021-00646-w"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"25.\tMasson D, Leleu D, Farnier M, Chagu\u00e9 F, Rampon C, Bichat F, Demeule C, Maza M, Pais de Barros JP, Cottin Y, Zeller M. Negative relationship between eicosapentaenoic acid and inflammatory biomarkers in patients with acute myocardial infarction. Cardiovasc Res. 2024;120:111-113. https:\/\/doi.org\/10.1093\/cvr\/cvae007","DOI":"10.1093\/cvr\/cvae007"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"26.\tWahid A, Chen W, Wang X, Tang X. High-mobility group box 1 serves as an inflammation driver of cardiovascular disease. Biomed Pharmacother. 2021;139:111555. https:\/\/doi.org\/10.1016\/j.biopha.2021.111555","DOI":"10.1016\/j.biopha.2021.111555"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"27.\tGuzik TJ, Nosalski R, Maffia P, Drummond GR. Immune and inflammatory mechanisms in hypertension. Nat Rev Cardiol. 2024;21:396-416. https:\/\/doi.org\/10.1038\/s41569-023-00964-1","DOI":"10.1038\/s41569-023-00964-1"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"28.\tYang Y, Yang L, Jiang S, Yang T, Lan J, Lei Y, Tan H, Pan K. HMGB1 mediates lipopolysaccharide-induced inflammation via interacting with GPX4 in colon cancer cells. Cancer Cell Int. 2020;20:205. https:\/\/doi.org\/10.1186\/s12935-020-01289-6","DOI":"10.1186\/s12935-020-01289-6"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"29.\tBhat SM, Massey N, Shrestha D, Karriker LA, Jelesijevi\u0107 T, Wang C, Charavaryamath C. Transcriptomic and ultrastructural evidence indicate that anti-HMGB1 antibodies rescue organic dust-induced mitochondrial dysfunction. Cell Tissue Res. 2022;388:373-398. https:\/\/doi.org\/10.1007\/s00441-022-03602-3","DOI":"10.1007\/s00441-022-03602-3"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"30.\tTang D, Kang R, Livesey KM, Zeh HJ 3rd, Lotze MT. High mobility group box 1 (HMGB1) activates an autophagic response to oxidative stress. Antioxid Redox Signal. 2011;15:2185-2195. https:\/\/doi.org\/10.1089\/ars.2010.3666","DOI":"10.1089\/ars.2010.3666"}],"container-title":["Physiological Research"],"original-title":[],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T20:01:41Z","timestamp":1768248101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.biomed.cas.cz\/physiolres\/pdf\/2025\/74_S259.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":30,"URL":"https:\/\/doi.org\/10.33549\/physiolres.935718","relation":{},"ISSN":["0862-8408","1802-9973"],"issn-type":[{"value":"0862-8408","type":"print"},{"value":"1802-9973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]}}}